Art. -Nr.: HY-136453

CR-1-31-B

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.38%
CAS. Nr.: 1352914-52-3
Formel: C₂₈H₂₉NO₈
Molecular Weight:507.53

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CR-1-31-B Chemical Structure

CAS. Nr.: 1352914-52-3

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

eIF4

Cellular Effect

Cell Line	Type	Value	Description	References
BJAB	IC₅₀	0.5 nM Compound: (-)-9, JAP-CR-1-31-B	Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 72 hr by scintillation counting Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 72 hr by scintillation counting	[PMID: 22128783]
BJAB	IC₅₀	1.5 nM Compound: (-)-9, JAP-CR-1-31-B	Cytotoxicity against human BJAB cells after 72 hrs by PI-staining based flow cytometric analysis Cytotoxicity against human BJAB cells after 72 hrs by PI-staining based flow cytometric analysis	[PMID: 22128783]
BJAB	IC₅₀	20 nM Compound: (-)-9, JAP-CR-1-31-B	Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 1 hr by scintillation counting Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 1 hr by scintillation counting	[PMID: 22128783]
HepG2	CC₅₀	14.3 nM Compound: rac-1c; (+/-)-CR-31-B	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 38127656]
HepG2	CC₅₀	188.3 nM Compound: rac-1c; (+/-)-CR-31-B	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 38127656]
NIH3T3	IC₅₀	9 nM Compound: 9; CR-1-31-B	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 4 days by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 4 days by SRB assay	[PMID: 33592144]

In Vitro

CR-1-31-B (100 nM; 24 hours) inhibits MUC1-C translation in MCF-10A cells (EGF-stimulated)^[1].
CR-1-31-B (10 and 100 nM) decreases MUC1-C abundance in MDA-MB-468 breast cancer cells^[1].
CR-1-31B sensitizes gallbladder cancer cells to TRAIL-mediated apoptosis through the translational downregulation of c-FLIP^[2].
Neuroblastoma (NB) cell lines exhibit decreased viability, increased apoptosis rates as well as changes in cell cycle distribution when treated with the synthetic rocaglate CR-1-31-B (24-72 hours), which clamps eIF4A and eIF4F onto mRNA, resulting in a translational block^[4].
CR-1-31-B (100 nM; 5 hours) treatment increases reverse glutamine metabolism in pancreatic cancer cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MCF-10A cells (EGF-stimulated)
Concentration:

100 nM
Incubation Time:

24 hours
Result:

Blocked increases in MUC1-C abundance.

Cell Viability Assay^[4]

Cell Line:

SH-SY5Y cells and Kelly cells
Concentration:

0.1-100 nM
Incubation Time:

24-72 hours
Result:

A significant decrease in SH-SY5Y viability was observed at 10 nM for all time points. Significantly decreased the viability of Kelly cells at 5 nM. The calculated IC₅₀ at 48 h was 20 nM for SH-SY5Y and 4 nM for Kelly cells.

Apoptosis Analysis^[4]

Cell Line:

SH-SY5Y and Kelly cells
Concentration:

SH-SY5Y cells were treated with 10, 20, and 50 nM and Kelly cells with 1, 5, and 10 nM
Incubation Time:

24-72 hours
Result:

Triggered apoptosis.

In Vivo

CR-1-31-B (2 mg/kg in 60 μL olive oil; IP; once every 2 days for 28 days) reduces the growth and initiates TRAIL-induced apoptosis in a BALB/c nude mice model of gallbladder cancer cells (GBC)^[2].
CR-1-31-B (0.2 mg/kg; IP; daily for 7 days; murine orthotopic transplant model of pancreatic ductal adenocarcinoma) effectively inhibits protein synthesis and growth of pancreatic tumours^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1352914-52-3
Appearance Solid
Molecular Weight 507.53
Formel C₂₈H₂₉NO₈
Color White to off-white
SMILES

O=C([C@H]([C@H]1C2=CC=CC=C2)[C@@H](O)[C@]3(O)[C@@]1(C4=CC=C(OC)C=C4)OC5=CC(OC)=CC(OC)=C35)NOC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (12)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation. [Abstract]

2025 Sep 4:e06925. PMID: 40908584
J Exp Clin Cancer Res

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. [Abstract]

2022 Dec 9;41(1):340. PMID: 36482393
Clin Cancer Res

Pharmacologic inhibition of eIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis. [Abstract]

2024 Oct 1;30(19):4464-4481. PMID: 39078310
Proc Natl Acad Sci U S A

eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations. [Abstract]

2024 Oct 29;121(44):e2321305121. PMID: 39436655
Cell Rep

Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. [Abstract]

2026 Jun 23;45(6):117520. PMID: 42284146
Cell Rep

PPARγ-dependent remodeling of translational machinery in adipose progenitors is impaired in obesity. [Abstract]

2024 Dec 24;43(12):114945. PMID: 39579770
Int J Mol Sci

eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. [Abstract]

2023 Jan 20;24(3):2055. PMID: 36768380
iScience

Programmable modulation of ribosomal frameshifting by mRNA targeting CRISPR-Cas12a system. [Abstract]

2023 Nov 19;26(12):108492. PMID: 38125012
bioRxiv

2025 Nov 18.
University of Cincinnati

2025.
Université de Montréal

2023 Aug.
Research Square Preprint

2022 Jun.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 230 mg/mL (453.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9703 mL

9.8516 mL

19.7033 mL

5 mM

0.3941 mL

1.9703 mL

3.9407 mL

10 mM

0.1970 mL

0.9852 mL

1.9703 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Konzentration

Volumen

Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5.75 mg/mL (11.33 mM); Clear solution

This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5.75 mg/mL (11.33 mM); Clear solution

This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5.75 mg/mL (11.33 mM); Clear solution

This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013;32(17):2179-2188. [Content Brief]

[2]. Cao Y, et al. Targeting eIF4A using rocaglate CR 1 31B sensitizes gallbladder cancer cells to TRAIL mediated apoptosis through the translational downregulation of c FLIP. Oncol Rep. 2021;45(1):230-238. [Content Brief]

[3]. Langlais D, et al. Rocaglates as dual-targeting agents for experimental cerebral malaria. Proc Natl Acad Sci U S A. 2018;115(10):E2366-E2375. [Content Brief]

[4]. Skofler C, et al. Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma. Cells. 2021;10(2):301. Published 2021 Feb 2. [Content Brief]

[5]. Chan K, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nat Commun. 2019;10(1):5151. Published 2019 Nov 13. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9703 mL	9.8516 mL	19.7033 mL	49.2582 mL
	5 mM	0.3941 mL	1.9703 mL	3.9407 mL	9.8516 mL
	10 mM	0.1970 mL	0.9852 mL	1.9703 mL	4.9258 mL
	15 mM	0.1314 mL	0.6568 mL	1.3136 mL	3.2839 mL
	20 mM	0.0985 mL	0.4926 mL	0.9852 mL	2.4629 mL
	25 mM	0.0788 mL	0.3941 mL	0.7881 mL	1.9703 mL
	30 mM	0.0657 mL	0.3284 mL	0.6568 mL	1.6419 mL
	40 mM	0.0493 mL	0.2463 mL	0.4926 mL	1.2315 mL
	50 mM	0.0394 mL	0.1970 mL	0.3941 mL	0.9852 mL
	60 mM	0.0328 mL	0.1642 mL	0.3284 mL	0.8210 mL
	80 mM	0.0246 mL	0.1231 mL	0.2463 mL	0.6157 mL
	100 mM	0.0197 mL	0.0985 mL	0.1970 mL	0.4926 mL

CR-1-31-B

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CR-1-31-B

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) CR-1-31-B

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CR-1-31-B

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) CR-1-31-B

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CR-1-31-B Related Classifications

Art. -Nr.: HY-136453